To investigate the TCP1 role in drug sensitivity for AML cells, we first evaluated the viability of HL60, K562 cells, and their respective multidrug-resistant cells (HL60/A and K562/A) cultured with different ADM concentrations. Here, TCP1 is linked to acute myeloid leukemia.